Je was op zoek naar: multicenterstudie (Deens - Engels)

iii-multicenterstudie.
placebo-controlled multicentre study.

i et randomiseret dobbeltblindet aktivkontrolleret klinisk multicenterstudie fik 635 patienter moderat kvalmefremkaldende cancerkemoterapi.
in a multicentre, randomised, double-blind active control clinical trial of 635 patients set to receive moderately emetogenic cancer chemotherapy.

der er udført ét pivotalt, åbent, kontrolleret multicenterstudie med patienter med turners syndrom.
one pivotal, multicentre, open label, controlled study has been conducted in turner syndrome.

blincyto blev undersøgt i et åbent fase ii-multicenterstudie med en enkelt behandlingsarm med 189 patienter.
blincyto was evaluated in an open-label, multicentre, single-arm phase ii study of 189 patients.

lal-cl02 var et dobbeltblindt, placebokontrolleret multicenterstudie hos 66 børn og voksne med lal-mangel.
lal-cl02 was a multicentre, double-blind, placebo-controlled study in 66 children and adults with lal deficiency.

cabometyx’s sikkerhed og virkning blev evalueret i et randomiseret, åbent fase iii-multicenterstudie.
the safety and efficacy of cabometyx were evaluated in a randomized, open-label, multicenter phase 3 study.

et fem-årigt langtidsopfølgende observationsstudie indrullerede 94 pædiatriske patienter med kronisk hepatitis c efter behandling i et multicenterstudie.
a five-year long-term, observational, follow-up study enrolled 94 paediatric chronic hepatitis c patients after treatment in a multicentre trial.

de nedenfor beskrevne data afspejler eksponeringen for tasigna hos 438 patienter i et open- label -, multicenterstudie.
the data described below reflect exposure to tasigna in 438 patients in an open-label multicentre study.

26 lungetransplantation interimanalysen af et nyligt afsluttet multicenterstudie omfatter 110 patienter der blev randomiseret i forholdet 1: 1 til enten tacrolimus eller ciclosporin.
lung transplantation the interim analysis of a recent multicentre study discussed 110 patients who underwent 1:1 randomisation to either tacrolimus or ciclosporin.

der blev udført et randomiseret, åbent multicenterstudie med 2.098 anæmiske kvinder med metastatisk brystcancer, der fik førstelinje eller andenlinje kemoterapi.
a randomised, open-label, multicentre study was conducted in 2,098 anaemic women with metastatic breast cancer, who received first line or second line chemotherapy.

et stort dobbeltblindet multicenterstudie omfattede de 3.171 patienter, som blev inkluderet i den akutte fase af ustabil angina eller myokardieinfarkt uden q-taksudvikling.
in a large multicentre, double-blind study, they examined 3,171 patients admitted in the acute phase of unstable angina or non-q-wave myocardial infarction.

fact- studiet (febuxostat allopurinol controlled trial) var et fase iii, randomiseret, dobbeltblind, multicenterstudie over 52 uger.
the febuxostat allopurinol controlled trial (fact) study was a phase 3, randomized, double-blind, multicenter, 52-week study.

et dobbeltblindet, ezetimibe-kontrolleret multicenterstudie af 24 ugers varighed omfattede 248 patients med dokumenteret statin-intolerans på grund af symptomer relateret til skeletmuskulaturen.
a multicenter, double-blind, ezetimibe-controlled, 24 week study included 248 patients with documented statin intolerance due to skeletal muscle-related symptoms.

humiras sikkerhed og virkning blev vurderet i et randomiseret, dobbeltblindet multicenterstudie hos 46 pædiatriske patienter (6-17 år) med moderat entesopatirelateret artrit.
the safety and efficacy of humira were assessed in a multicenter, randomised, double-blind study in 46 paediatric patients (6 to 17 years old) with moderate enthesitis-related arthritis.

apex- studiet (allopurinol and placebo- controlled efficacy study of febuxostat) var et fase iii, randomiseret, dobbeltblind, multicenterstudie over 28 uger.
the allopurinol and placebo-controlled efficacy study of febuxostat (apex) was a phase 3, randomized, double-blind, multicenter, 28-week study.

data fra et randomiseret, kontrolleret, klinisk fase iii- multicenterstudie hos patienter med fremskreden ventrikelkræft støtter anvendelsen af xeloda som 1. linjebehandling af fremskreden ventrikelkræft (ml17032).
data from a multicentre, randomised, controlled phase iii clinical trial in patients with advanced gastric cancer supports the use of xeloda for the first-line treatment of advanced gastric cancer (ml17032).